Author Archives: Marisa Wexler MS

Guidelines Given for Rituximab as Maintenance Therapy in 3 AAV Subtypes

Guidelines for using rituximab as a maintenance therapy in adults with ANCA-associated vasculitis (AAV) were recently published that, in addition to helping physicians with treatment approaches, highlight areas where more research is needed. “Rituximab for maintenance of remission in ANCA-associated vasculitis: expert consensus guidelines,” was…

Trial Supports Long-term Maintenance Therapy With Rituximab

Continuing maintenance treatment with rituximab for long periods increases the likelihood that people with ANCA-associated vasculitis (AAV) remain in remission, without increasing the incidence or severity of adverse events, findings from a Phase 3 trial show. The study, “Long-Term Rituximab Use to Maintain Remission of…

AAV That Involves Central Nervous System Linked to More Active Disease, Chinese Study Suggests

In people with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), central nervous system involvement is associated with more active disease and peripheral nervous system involvement, a recent Chinese study suggests. The study, “Central nervous system involvement in patients with antineutrophil cytoplasmic antibody–associated vasculitis: a study of 29…

AAV Patients Treated According to Guidelines, With Infection Most Common Side Effect, Polish Study Reports

People in Poland with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV) are treated according to existing guidelines, and the most common treatment-associated adverse event is infection, according to a nationwide study. The study, “Treatment and its side effects in ANCA-associated vasculitides – Study based on POLVAS registry…